Ifosfamide encephalopathy and use of methylene blue. A case report of different sequential neurotoxicity
Neurotoxicity is a clinically relevant adverse event observed with the use of ifosfamide. It is usually mild, occasionally severe and seldom fatal. Ifosfamide-induced encephalopathy requires interruption of chemotherapy, intravenous hydration and administration of methylene blue. Less is known about...
Gespeichert in:
| Veröffentlicht in: | Tumori 2009-07, Vol.95 (4), p.545-546 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 546 |
|---|---|
| container_issue | 4 |
| container_start_page | 545 |
| container_title | Tumori |
| container_volume | 95 |
| creator | Giovanis, Petros Garna, Antonella Marcante, Marilisa Nardi, Katiuscia Giusto, Mauro |
| description | Neurotoxicity is a clinically relevant adverse event observed with the use of ifosfamide. It is usually mild, occasionally severe and seldom fatal. Ifosfamide-induced encephalopathy requires interruption of chemotherapy, intravenous hydration and administration of methylene blue. Less is known about the efficacy of methylene blue in avoiding a second episode of ifosfamide-induced encephalopathy while maintaining chemotherapy with ifosfamide. We report a case of a different clinical manifestation of ifosfamide-induced encephalopathy after continued ifosfamide use and despite methylene blue in a patient with retroperitoneal sarcoma. |
| doi_str_mv | 10.1177/030089160909500426 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1177_030089160909500426</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>19856674</sourcerecordid><originalsourceid>FETCH-LOGICAL-c301t-3a1cd04b19c77cafa11ebbf1217d581339150ba2fa7576bcf31f247a9090d3c43</originalsourceid><addsrcrecordid>eNplkM1Kw0AUhQdRbK2-gAuZF0i9dyaZSZalaC0U3Og6TCZ3aCR_ziRg396EFly4OnDud-7iY-wRYY2o9TNIgDRDBRlkCUAs1BVbCpBpJBKRXbPlDEQzsWB3IXxNCAilbtkCszRRSsdLdty7LjjTVCVxai31R1N3vRmOJ27ako-BeOd4Q1NRU0u8qEda8w23Zrp46js_zEBZOUee2oEH-h6nrEzNWxp9N3Q_la2G0z27caYO9HDJFft8ffnYvkWH991-uzlEVgIOkTRoS4gLzKzW1jiDSEXhUKAukxSlzDCBwghndKJVYZ1EJ2JtJgVQShvLFRPnv9Z3IXhyee-rxvhTjpDP2vL_2qbR03nUj0VD5d_k4kn-Al7zaYA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Ifosfamide encephalopathy and use of methylene blue. A case report of different sequential neurotoxicity</title><source>Access via SAGE</source><source>MEDLINE</source><creator>Giovanis, Petros ; Garna, Antonella ; Marcante, Marilisa ; Nardi, Katiuscia ; Giusto, Mauro</creator><creatorcontrib>Giovanis, Petros ; Garna, Antonella ; Marcante, Marilisa ; Nardi, Katiuscia ; Giusto, Mauro</creatorcontrib><description>Neurotoxicity is a clinically relevant adverse event observed with the use of ifosfamide. It is usually mild, occasionally severe and seldom fatal. Ifosfamide-induced encephalopathy requires interruption of chemotherapy, intravenous hydration and administration of methylene blue. Less is known about the efficacy of methylene blue in avoiding a second episode of ifosfamide-induced encephalopathy while maintaining chemotherapy with ifosfamide. We report a case of a different clinical manifestation of ifosfamide-induced encephalopathy after continued ifosfamide use and despite methylene blue in a patient with retroperitoneal sarcoma.</description><identifier>ISSN: 0300-8916</identifier><identifier>EISSN: 2038-2529</identifier><identifier>DOI: 10.1177/030089160909500426</identifier><identifier>PMID: 19856674</identifier><language>eng</language><publisher>United States</publisher><subject>Antineoplastic Agents, Alkylating - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Enzyme Inhibitors - therapeutic use ; Female ; Humans ; Ifosfamide - adverse effects ; Methylene Blue - therapeutic use ; Middle Aged ; Neurotoxicity Syndromes - drug therapy ; Neurotoxicity Syndromes - etiology ; Retroperitoneal Neoplasms - drug therapy ; Retroperitoneal Neoplasms - physiopathology ; Sarcoma - drug therapy ; Sarcoma - physiopathology</subject><ispartof>Tumori, 2009-07, Vol.95 (4), p.545-546</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c301t-3a1cd04b19c77cafa11ebbf1217d581339150ba2fa7576bcf31f247a9090d3c43</citedby><cites>FETCH-LOGICAL-c301t-3a1cd04b19c77cafa11ebbf1217d581339150ba2fa7576bcf31f247a9090d3c43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,27929,27930</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19856674$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Giovanis, Petros</creatorcontrib><creatorcontrib>Garna, Antonella</creatorcontrib><creatorcontrib>Marcante, Marilisa</creatorcontrib><creatorcontrib>Nardi, Katiuscia</creatorcontrib><creatorcontrib>Giusto, Mauro</creatorcontrib><title>Ifosfamide encephalopathy and use of methylene blue. A case report of different sequential neurotoxicity</title><title>Tumori</title><addtitle>Tumori</addtitle><description>Neurotoxicity is a clinically relevant adverse event observed with the use of ifosfamide. It is usually mild, occasionally severe and seldom fatal. Ifosfamide-induced encephalopathy requires interruption of chemotherapy, intravenous hydration and administration of methylene blue. Less is known about the efficacy of methylene blue in avoiding a second episode of ifosfamide-induced encephalopathy while maintaining chemotherapy with ifosfamide. We report a case of a different clinical manifestation of ifosfamide-induced encephalopathy after continued ifosfamide use and despite methylene blue in a patient with retroperitoneal sarcoma.</description><subject>Antineoplastic Agents, Alkylating - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Enzyme Inhibitors - therapeutic use</subject><subject>Female</subject><subject>Humans</subject><subject>Ifosfamide - adverse effects</subject><subject>Methylene Blue - therapeutic use</subject><subject>Middle Aged</subject><subject>Neurotoxicity Syndromes - drug therapy</subject><subject>Neurotoxicity Syndromes - etiology</subject><subject>Retroperitoneal Neoplasms - drug therapy</subject><subject>Retroperitoneal Neoplasms - physiopathology</subject><subject>Sarcoma - drug therapy</subject><subject>Sarcoma - physiopathology</subject><issn>0300-8916</issn><issn>2038-2529</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNplkM1Kw0AUhQdRbK2-gAuZF0i9dyaZSZalaC0U3Og6TCZ3aCR_ziRg396EFly4OnDud-7iY-wRYY2o9TNIgDRDBRlkCUAs1BVbCpBpJBKRXbPlDEQzsWB3IXxNCAilbtkCszRRSsdLdty7LjjTVCVxai31R1N3vRmOJ27ako-BeOd4Q1NRU0u8qEda8w23Zrp46js_zEBZOUee2oEH-h6nrEzNWxp9N3Q_la2G0z27caYO9HDJFft8ffnYvkWH991-uzlEVgIOkTRoS4gLzKzW1jiDSEXhUKAukxSlzDCBwghndKJVYZ1EJ2JtJgVQShvLFRPnv9Z3IXhyee-rxvhTjpDP2vL_2qbR03nUj0VD5d_k4kn-Al7zaYA</recordid><startdate>20090701</startdate><enddate>20090701</enddate><creator>Giovanis, Petros</creator><creator>Garna, Antonella</creator><creator>Marcante, Marilisa</creator><creator>Nardi, Katiuscia</creator><creator>Giusto, Mauro</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20090701</creationdate><title>Ifosfamide encephalopathy and use of methylene blue. A case report of different sequential neurotoxicity</title><author>Giovanis, Petros ; Garna, Antonella ; Marcante, Marilisa ; Nardi, Katiuscia ; Giusto, Mauro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c301t-3a1cd04b19c77cafa11ebbf1217d581339150ba2fa7576bcf31f247a9090d3c43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Antineoplastic Agents, Alkylating - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Enzyme Inhibitors - therapeutic use</topic><topic>Female</topic><topic>Humans</topic><topic>Ifosfamide - adverse effects</topic><topic>Methylene Blue - therapeutic use</topic><topic>Middle Aged</topic><topic>Neurotoxicity Syndromes - drug therapy</topic><topic>Neurotoxicity Syndromes - etiology</topic><topic>Retroperitoneal Neoplasms - drug therapy</topic><topic>Retroperitoneal Neoplasms - physiopathology</topic><topic>Sarcoma - drug therapy</topic><topic>Sarcoma - physiopathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Giovanis, Petros</creatorcontrib><creatorcontrib>Garna, Antonella</creatorcontrib><creatorcontrib>Marcante, Marilisa</creatorcontrib><creatorcontrib>Nardi, Katiuscia</creatorcontrib><creatorcontrib>Giusto, Mauro</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Tumori</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Giovanis, Petros</au><au>Garna, Antonella</au><au>Marcante, Marilisa</au><au>Nardi, Katiuscia</au><au>Giusto, Mauro</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Ifosfamide encephalopathy and use of methylene blue. A case report of different sequential neurotoxicity</atitle><jtitle>Tumori</jtitle><addtitle>Tumori</addtitle><date>2009-07-01</date><risdate>2009</risdate><volume>95</volume><issue>4</issue><spage>545</spage><epage>546</epage><pages>545-546</pages><issn>0300-8916</issn><eissn>2038-2529</eissn><abstract>Neurotoxicity is a clinically relevant adverse event observed with the use of ifosfamide. It is usually mild, occasionally severe and seldom fatal. Ifosfamide-induced encephalopathy requires interruption of chemotherapy, intravenous hydration and administration of methylene blue. Less is known about the efficacy of methylene blue in avoiding a second episode of ifosfamide-induced encephalopathy while maintaining chemotherapy with ifosfamide. We report a case of a different clinical manifestation of ifosfamide-induced encephalopathy after continued ifosfamide use and despite methylene blue in a patient with retroperitoneal sarcoma.</abstract><cop>United States</cop><pmid>19856674</pmid><doi>10.1177/030089160909500426</doi><tpages>2</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0300-8916 |
| ispartof | Tumori, 2009-07, Vol.95 (4), p.545-546 |
| issn | 0300-8916 2038-2529 |
| language | eng |
| recordid | cdi_crossref_primary_10_1177_030089160909500426 |
| source | Access via SAGE; MEDLINE |
| subjects | Antineoplastic Agents, Alkylating - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Enzyme Inhibitors - therapeutic use Female Humans Ifosfamide - adverse effects Methylene Blue - therapeutic use Middle Aged Neurotoxicity Syndromes - drug therapy Neurotoxicity Syndromes - etiology Retroperitoneal Neoplasms - drug therapy Retroperitoneal Neoplasms - physiopathology Sarcoma - drug therapy Sarcoma - physiopathology |
| title | Ifosfamide encephalopathy and use of methylene blue. A case report of different sequential neurotoxicity |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-12T17%3A46%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Ifosfamide%20encephalopathy%20and%20use%20of%20methylene%20blue.%20A%20case%20report%20of%20different%20sequential%20neurotoxicity&rft.jtitle=Tumori&rft.au=Giovanis,%20Petros&rft.date=2009-07-01&rft.volume=95&rft.issue=4&rft.spage=545&rft.epage=546&rft.pages=545-546&rft.issn=0300-8916&rft.eissn=2038-2529&rft_id=info:doi/10.1177/030089160909500426&rft_dat=%3Cpubmed_cross%3E19856674%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/19856674&rfr_iscdi=true |